Arthur A M Wilde

List of Publications by Year in Descending Order

352 papers	32,366 citations	100 h-index	173 g-index
393 ext. papers	39,109 ext. citations	7.8 avg, IF	6.99 L-index

#	Paper	IF	Citations
352	Arrhythmogenic Right Ventricular Cardiomyopathy.. *JACC: Clinical Electrophysiology*, **2022**, 8, 533-553	4.6	1
351	A deep learning approach identifies new ECG features in congenital long QT syndrome.. *BMC Medicine*, **2022**, 20, 162	11.4	0
350	Prevalence of Short-Coupled Ventricular Fibrillation in a Large Cohort of Dutch Patients With Idiopathic Ventricular Fibrillation.. *Circulation*, **2022**, 145, 1437-1439	16.7	2
349	Andersen-Tawil syndrome: Overlapping clinical features with Noonan syndrome?. *European Journal of Medical Genetics*, **2021**, 65, 104382	2.6	
348	Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. *JAMA Cardiology*, **2021**,	16.2	3
347	Avoiding fatal implantable cardioverter-defibrillator complications in patients with catecholaminergic polymorphic ventricular tachycardia by not implanting them. *Journal of Electrocardiology*, **2021**, 70, 2-3	1.4	
346	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: An Analysis of All Appropriate Therapy in the PRAETORIAN trial. *Circulation*, **2021**,	16.7	3
345	A phenotype-enhanced variant classification framework to decrease the burden of missense variants of uncertain significance in type 1 long QT syndrome. *Heart Rhythm*, **2021**,	6.7	1
344	Pregnancy in women with Brugada syndrome: Is there an increased arrhythmia risk? A case-series report. *Journal of Cardiovascular Electrophysiology*, **2021**,	2.7	1
343	Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review. *BMJ Open Sport and Exercise Medicine*, **2021**, 7, e001164	3.4	3
342	Two siblings with early repolarization syndrome: clinical and genetic characterization by whole-exome sequencing. *Europace*, **2021**, 23, 775-780	3.9	0
341	The Netherlands Sports Cardiology Map: a step towards sports cardiology network medicine for patient and athlete care. *Netherlands Heart Journal*, **2021**, 29, 129-134	2.2	1
340	Life-threatening arrhythmias with autosomal recessive TECRL variants. *Europace*, **2021**, 23, 781-788	3.9	5
339	Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort. *Journal of the American Heart Association*, **2021**, 10, e018063	6	2
338	Improving electrocardiogram-based detection of rare genetic heart disease using transfer learning: An application to phospholamban p.Arg14del mutation carriers. *Computers in Biology and Medicine*, **2021**, 131, 104262	7	6
337	Importance of Dedicated Units for the Management of Patients With Inherited Arrhythmia Syndromes. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003313	5.2	2
336	Diagnosis, management and therapeutic strategies for congenital long QT syndrome. *Heart*, **2021**,	5.1	11

335	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. *European Heart Journal*, **2021**, 42, 2842-2850	9.5	7
334	Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). *Netherlands Heart Journal*, **2021**, 1	2.2	3
333	The □angle can help guide clinical decisions in the diagnostic work-up of patients suspected of Brugada syndrome: a validation study of the □angle in determining the outcome of a sodium channel provocation test. *Europace*, **2021**, 23, 2020-2028	3.9	1
332	Management of Congenital Long-QT Syndrome: Commentary From the Experts. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e009726	6.4	2
331	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. *Heart Rhythm*, **2021**, 18, e1-e50	6.7	37
330	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e008509	6.4	21
329	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. *Journal of Arrhythmia*, **2021**, 37, 481-534	1.5	3
328	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. *Heart Rhythm*, **2021**, 18, 79-87	6.7	7
327	Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?. *European Heart Journal*, **2021**, 42, 1073-1081	9.5	17
326	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. *European Heart Journal*, **2021**,	9.5	28
325	BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants-design and status. *Netherlands Heart Journal* , **2021**, 29, 318-329	2.2	2
324	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. *Europace*, **2021**, 23, 887-897	3.9	7
323	Cardiac ryanodine receptor calcium release deficiency syndrome. *Science Translational Medicine*, **2021**, 13,	17.5	18
322	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2021**, 18, 1825-1832	6.7	3
321	Investigation on Sudden Unexpected Death in the Young (SUDY) in Europe: results of the European Heart Rhythm Association Survey. *Europace*, **2021**,	3.9	4
320	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. *Circulation*, **2021**, 144, 1600-1611	16.7	3
319	Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations: Clinical Phenotypes and In Vitro Characterization. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e010013	6.4	2
318	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. *European Heart Journal*, **2021**,	9.5	5

317	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. *Europace*, **2021**,	3.9	1
316	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, **2021**, 53, 128-134	36.3	35
315	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. *Cardiovascular Research*, **2021**,	9.9	3
314	Structurally Abnormal Myocardium Underlies Ventricular Fibrillation Storms in a Patient Diagnosed With the Early Repolarization Pattern. *JACC: Clinical Electrophysiology*, **2020**, 6, 1395-1404	4.6	8
313	Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in Families. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002911	5.2	13
312	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27
311	Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. *Heart Rhythm*, **2020**, 17, 1487-1492	6.7	46
310	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.	3.9	25
309	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. *Heart Rhythm*, **2020**, 17, e269-e316	6.7	7
308	Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. *Heart Rhythm*, **2020**, 17, 2145-2153	6.7	8
307	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. *Heart Rhythm*, **2020**, 17, 1480-1486	6.7	18
306	In Children and Adolescents From Brugada Syndrome-Families, Only Mutation Carriers Develop a Type-1 ECG Pattern Induced By Fever. *Circulation*, **2020**, 142, 89-91	16.7	5
305	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. *Circulation*, **2020**, 141, 429-439	16.7	15
304	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. *Circulation*, **2020**, 141, 418-428	16.7	95
303	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. *Heart Rhythm*, **2020**, 17, 1456-1462	6.7	115
302	Importance of Validating Guideline Recommendations. *Circulation Journal*, **2020**, 84, 2136-2137	2.9	
301	Biomarkers in inherited arrhythmias: necessity for validation and collaboration. *European Heart Journal*, **2020**, 41, 4523-4524	9.5	
300	Improving long QT syndrome diagnosis by a polynomial-based T-wave morphology characterization. *Heart Rhythm*, **2020**, 17, 752-758	6.7	10

299	50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - Time to Explore the Dark Side of the Moon. *Heart Lung and Circulation*, **2020**, 29, 520-528	1.8	8
298	In memory of Hein Wellens: unique scientist, teacher, doctor and friend. *Netherlands Heart Journal*, **2020**, 28, 439-440	2.2	0
297	Inherited cardiac arrhythmias. *Nature Reviews Disease Primers*, **2020**, 6, 58	51.1	53
296	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of -Catecholaminergic Polymorphic Ventricular Tachycardia. *Circulation*, **2020**, 142, 932-947	16.7	12
295	Subcutaneous or Transvenous Defibrillator Therapy. *New England Journal of Medicine*, **2020**, 383, 526-536	59.2	99
294	Cardiogenetics, 25 years a growing subspecialism. *Netherlands Heart Journal*, **2020**, 28, 39-43	2.2	2
293	The yield of postmortem genetic testing in sudden death cases with structural findings at autopsy. *European Journal of Human Genetics*, **2020**, 28, 17-22	5.3	16
292	Caring for the pregnant woman with an inherited arrhythmia syndrome. *Heart Rhythm*, **2020**, 17, 341-348	6.7	16
291	Epidemiology of inherited arrhythmias. *Nature Reviews Cardiology*, **2020**, 17, 205-215	14.8	18
290	Catheter ablation in highly symptomatic Brugada patients: a Dutch case series. *Clinical Research in Cardiology*, **2020**, 109, 560-569	6.1	4
289	Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores. *European Heart Journal*, **2019**, 40, 3097-3107	9.5	33
288	Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients. *Europace*, **2019**, 21, 1519-1526	3.9	7
287	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. *American Heart Journal*, **2019**, 214, 167-174	4.9	22
286	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. *European Heart Journal*, **2019**, 40, 2964-2975	9.5	61
285	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. *European Heart Journal*, **2019**, 40, 2953-2961	9.5	53
284	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
283	Impact of Leadless Pacemaker Therapy on Cardiac and Atrioventricular Valve Function Through 12 Months of Follow-Up. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12, e007124	6.4	27
282	Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002510	5.2	19

281	The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update. *Netherlands Heart Journal*, **2019**, 27, 480-486	2.2	13
280	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. *European Heart Journal*, **2019**, 40, 1850-1858	9.5	104
279	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1756-1765	15.1	33
278	Response by Wilde and Gollob to Letter Regarding Article, "Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome". *Circulation*, **2019**, 139, 1760-1761	16.7	5
277	Using registries to predict outcome: the implantable cardioverter-defibrillator in long QT syndrome. *Europace*, **2019**, 21, 188-189	3.9	1
276	Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site. *Europace*, **2019**, 21, 1725-1732	3.9	9
275	Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy. *BMC Cardiovascular Disorders*, **2019**, 19, 174	2.3	5
274	European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. *European Journal of Human Genetics*, **2019**, 27, 1763-1773	5.3	31
273	Heritability in genetic heart disease: the role of genetic background. *Open Heart*, **2019**, 6, e000929	3	7
272	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
271	Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantable-defibrillator patients. *Journal of Cardiovascular Electrophysiology*, **2019**, 30, 2441-2447	2.7	6
270	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. *Journal of Clinical Investigation*, **2019**, 129, 3171-3184	15.9	23
269	Creating certainty out of uncertainty. *European Heart Journal*, **2019**, 40, 839-841	9.5	1
268	Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. *JACC: Clinical Electrophysiology*, **2019**, 5, 387-394	4.6	11
267	Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. *Heart Lung and Circulation*, **2019**, 28, 22-30	1.8	64
266	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. *Heart Rhythm*, **2019**, 16, 403-410	6.7	42
265	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 92-100	4.1	29
264	Left Ventricular Isovolumetric Relaxation Time Is Prolonged in Fetal Long-QT Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005797	6.4	8

263	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2018**, 15, 1394-1401	6.7	49
262	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. *Europace*, **2018**, 20, 1866-1871	3.9	11
261	Yield of the Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001424	5.2	20
260	Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. *Circulation*, **2018**, 137, 619-630	16.7	43
259	Athletes with channelopathy may be eligible to play. *Netherlands Heart Journal*, **2018**, 26, 146-153	2.2	3
258	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Heart Rhythm*, **2018**, 15, 716-724	6.7	36
257	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. *European Heart Journal*, **2018**, 39, 2898-2907	9.5	12
256	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. *International Journal of Cardiology*, **2018**, 266, 128-132	3.2	14
255	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1004-1009	2.7	10
254	The genetic architecture of long QT syndrome: A critical reappraisal. *Trends in Cardiovascular Medicine*, **2018**, 28, 453-464	6.9	58
253	The brisk-standing-test for long QT syndrome in prepubertal school children: defining normal. *Europace*, **2018**, 20, f108-f112	3.9	8
252	Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. *Circulation*, **2018**, 138, 1195-1205	16.7	158
251	SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. *European Heart Journal*, **2018**, 39, 2879-2887	9.5	18
250	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart Rhythm*, **2018**, 15, 1457-1465	6.7	36
249	Clinical parameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy. *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 990	1.6	4
248	Effect of age and gender on the QTc-interval in healthy individuals and patients with long-QT syndrome. *Trends in Cardiovascular Medicine*, **2018**, 28, 64-75	6.9	38
247	A comprehensive evaluation of the genetic architecture of sudden cardiac arrest. *European Heart Journal*, **2018**, 39, 3961-3969	9.5	31
246	Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients. *Netherlands Heart Journal*, **2018**, 26, 612-619	2.2	6

245	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001797	5.2	7
244	Support vector machine-based assessment of the T-wave morphology improves long QT syndrome diagnosis. *Europace*, **2018**, 20, iii113-iii119	3.9	7
243	Determination and Interpretation of the QT Interval. *Circulation*, **2018**, 138, 2345-2358	16.7	53
242	Health-related quality of life impact of a transcatheter pacing system. *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1697-1704	2.7	14
241	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. *PLoS ONE*, **2018**, 13, e0203078	3.7	2
240	A Potential Diagnostic Approach for Foetal Long-QT Syndrome, Developed and Validated in Children. *Pediatric Cardiology*, **2018**, 39, 1413-1422	2.1	1
239	Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator: An Evaluation of 4 Implantation Techniques. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10, e004663	6.4	37
238	Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. *Journal of the American College of Cardiology*, **2017**, 69, 2134-2145	15.1	126
237	Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 87-91	2.7	11
236	Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes. *Cardiovascular Research*, **2017**, 113, 829-838	9.9	28
235	The Brugada Syndrome Susceptibility Gene Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity. *Circulation Research*, **2017**, 121, 537-548	15.7	34
234	Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres. *Netherlands Heart Journal*, **2017**, 25, 312-317	2.2	7
233	Effect of Age and Sex on the QTc Interval in Children and Adolescents With Type 1 and 2 Long-QT Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	17
232	Familial Disease Is Not Always Genetic: A Family With Atrioventricular Block and Mitral Regurgitation. *Canadian Journal of Cardiology*, **2017**, 33, 554.e9-554.e11	3.8	
231	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Europace*, **2017**, 19, 665-694	3.9	127
230	Response by Veerman et al to Letter Regarding Article, "The Brugada Syndrome Susceptibility Gene Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity". *Circulation Research*, **2017**, 121, e21	15.7	
229	-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder Mutation. *Circulation: Cardiovascular Genetics*, **2017**, 10,		27
228	Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator. *Netherlands Heart Journal*, **2017**, 25, 574-580	2.2	9

227	Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death: Single-Center Experience With 482 Families. *JACC: Clinical Electrophysiology*, **2017**, 3, 1400-1408	4.6	19
226	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. *European Journal of Heart Failure*, **2017**, 19, 512-521	12.3	91
225	Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. *Open Heart*, **2017**, 4, e000551	3	10
224	Switch From Fetal to Adult Isoform in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Unmasks the Cellular Phenotype of a Conduction Disease-Causing Mutation. *Journal of the American Heart Association*, **2017**, 6,	6	34
223	The development and validation of an easy to use automatic QT-interval algorithm. *PLoS ONE*, **2017** , 12, e0184352	3.7	12
222	Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. *Heart Rhythm*, **2016**, 13, 443-54	6.7	143
221	Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1. *Heart Rhythm*, **2016**, 13, 122-31	6.7	14
220	Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. *Circulation*, **2016**, 134, 872-82	16.7	118
219	GNB5 Mutations Cause an Autosomal-Recessive Multisystem Syndrome with Sinus Bradycardia and Cognitive Disability. *American Journal of Human Genetics*, **2016**, 99, 704-710	11	34
218	Catecholaminergic Polymorphic Ventricular Tachycardia. *Circulation Journal*, **2016**, 80, 1285-91	2.9	54
217	Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes. *Journal of the American Heart Association*, **2016**, 5,	6	18
216	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Heart Rhythm*, **2016**, 13, e295-324	6.7	166
215	Long-Term Outcome of Patients Initially Diagnosed With Idiopathic Ventricular Fibrillation: A Descriptive Study. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	28
214	hiPSC-derived cardiomyocytes from Brugada Syndrome patients without identified mutations do not exhibit clear cellular electrophysiological abnormalities. *Scientific Reports*, **2016**, 6, 30967	4.9	50
213	Readthrough-Promoting Drugs Gentamicin and PTC124 Fail to Rescue Nav1.5 Function of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Carrying Nonsense Mutations in the Sodium Channel Gene SCN5A. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	20
212	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Journal of Arrhythmia*, **2016**, 32, 315-339	1.5	90
211	Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. *Journal of the American College of Cardiology*, **2016**, 68, 2047-2055	15.1	102
210	Asymmetry of parental origin in long QT syndrome: preferential maternal transmission of KCNQ1 variants linked to channel dysfunction. *European Journal of Human Genetics*, **2016**, 24, 1160-6	5.3	16

209	Prognostic significance of fever-induced Brugada syndrome. *Heart Rhythm*, **2016**, 13, 1515-20	6.7	46
208	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. *Heart Rhythm*, **2016**, 13, 1274-82	6.7	71
207	Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance. *Europace*, **2016**, 18, 1740-1747	3.9	51
206	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. *Heart Rhythm*, **2016**, 13, 905-12	6.7	28
205	Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. *Heart Rhythm*, **2016**, 13, 609-13	6.7	41
204	Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community-based intervention study. *Europace*, **2016**, 18, 592-601	3.9	21
203	Expert cardiologists cannot distinguish between Brugada phenocopy and Brugada syndrome electrocardiogram patterns. *Europace*, **2016**, 18, 1095-100	3.9	44
202	Relationship Between Cardiac Dysfunction and Cerebral Perfusion in Patients with Aneurysmal Subarachnoid Hemorrhage. *Neurocritical Care*, **2016**, 24, 202-6	3.3	22
201	The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. *Arrhythmia and Electrophysiology Review*, **2016**, 5, 45-9	3.2	13
200	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. *Heart*, **2016**, 102, 303-12	5.1	35
199	TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. *EMBO Molecular Medicine*, **2016**, 8, 1390-1408	12	68
198	Letter by Amin et al Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?". *Circulation: Cardiovascular Genetics*, **2016**, 9, 580		2
197	Idiopathic Ventricular Fibrillation: The Struggle for Definition, Diagnosis, and Follow-Up. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	38
196	Role of Genetic Testing in Patients with Ventricular Arrhythmias in Apparently Normal Hearts. *Cardiac Electrophysiology Clinics*, **2016**, 8, 515-23	1.4	0
195	Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. *Netherlands Heart Journal*, **2015**, 23, 182-9	2.2	4
194	Enhanced Classification of Brugada Syndrome-Associated and Long-QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium Channel. *Circulation: Cardiovascular Genetics*, **2015**, 8, 582-95		65
193	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. *Circulation: Cardiovascular Genetics*, **2015**, 8, 437-46		262
192	Postmortem Histopathological Examination of a Leadless Pacemaker Shows Partial Encapsulation After 19 Months. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 1293-5	6.4	17

191	Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. *Journal of the American College of Cardiology*, **2015**, 66, 1976-1986	15.1	216
190	Atlas of the clinical genetics of human dilated cardiomyopathy. *European Heart Journal*, **2015**, 36, 1123-35a	9.5	334
189	Genotype-phenotype analysis of Jervell and Lange-Nielsen syndrome in six families from Saudi Arabia. *Clinical Genetics*, **2015**, 87, 74-9	4	3
188	An unexpected ECG finding. *Netherlands Heart Journal*, **2015**, 23, 613-6	2.2	
187	Channelopathies - emerging trends in the management of inherited arrhythmias. *Indian Pacing and Electrophysiology Journal*, **2015**, 15, 43-54	1.5	5
186	An unexpected ECG finding. *Netherlands Heart Journal*, **2015**, 23, 608	2.2	
185	Quality of Life in Young Adult Patients with a Cardiogenetic Condition Receiving an ICD for Primary Prevention of Sudden Cardiac Death. *PACE - Pacing and Clinical Electrophysiology*, **2015**, 38, 870-7	1.6	8
184	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. *European Heart Journal*, **2015**, 36, 1290-6	9.5	144
183	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. *Circulation*, **2015**, 131, 2185-93	16.7	174
182	Inherited ion channel diseases: a brief review. *Europace*, **2015**, 17 Suppl 2, ii1-6	3.9	40
181	Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. *Cardiovascular Research*, **2015**, 106, 520-9	9.9	86
180	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. *European Heart Journal*, **2015**, 36, 847-55	9.5	238
179	A common arrhythmia, not so common at an old age. *Netherlands Heart Journal*, **2014**, 22, 88	2.2	
178	A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. *Journal of the American College of Cardiology*, **2014**, 63, 259-66	15.1	124
177	HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy. *Journal of the American College of Cardiology*, **2014**, 64, 745-56	15.1	133
176	Permanent leadless cardiac pacing: results of the LEADLESS trial. *Circulation*, **2014**, 129, 1466-71	16.7	192
175	Risk stratification for sudden cardiac death: current status and challenges for the future. *European Heart Journal*, **2014**, 35, 1642-51	9.5	240
174	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nature Genetics*, **2014**, 46, 826-36	36.3	199

173	Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. *Circulation: Cardiovascular Genetics*, **2014**, 7, 455-65		103
172	Low rate of cardiac events in first-degree relatives of diagnosis-negative young sudden unexplained death syndrome victims during follow-up. *Heart Rhythm*, **2014**, 11, 1728-32	6.7	25
171	Cardiac involvement in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study. *Muscle and Nerve*, **2014**, 50, 909-13	3.4	16
170	De novo mutation in the KCNQ1 gene causal to Jervell and Lange-Nielsen syndrome. *Clinical Genetics*, **2014**, 86, 492-5	4	5
169	Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. *Journal of Cardiovascular Electrophysiology*, **2014**, 25, 494-499	2.7	92
168	Value of serial heart rate variability measurement for prediction of appropriate ICD discharge in patients with heart failure. *Journal of Cardiovascular Electrophysiology*, **2014**, 25, 60-5	2.7	2
167	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. *Journal of Arrhythmia*, **2014**, 30, 29-47	1.5	8
166	Inherited arrhythmia syndromes leading to sudden cardiac death in the young: a global update and an Indian perspective. *Indian Heart Journal*, **2014**, 66 Suppl 1, S49-57	1.6	7
165	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. *Journal of Arrhythmia*, **2014**, 30, 1-28	1.5	11
164	Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. *Nature Genetics*, **2013**, 45, 1044-9	36.3	345
163	Genetic testing for inherited cardiac disease. *Nature Reviews Cardiology*, **2013**, 10, 571-83	14.8	115
162	Palpitations in a 19-year old man and a slow heart rate at rest. *Netherlands Heart Journal*, **2013**, 21, 310-310	2.2	78
161	Palpitations in a 19-year old man and a slow heart rate at rest. *Netherlands Heart Journal*, **2013**, 21, 313-313	2.2	78
160	An atypical arrhythmia. *Netherlands Heart Journal*, **2013**, 21, 255-255	2.2	78
159	An atypical arrhythmia. *Netherlands Heart Journal*, **2013**, 21, 262-262	2.2	78
158	Palpitations in a 19-year-old man, take a second look. *Netherlands Heart Journal*, **2013**, 21, 205-205	2.2	78
157	Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. *European Journal of Heart Failure*, **2013**, 15, 628-36	12.3	117
156	Palpitations, should one worry?. *Netherlands Heart Journal*, **2013**, 21, 159-160	2.2	78

155	Palpitations, should one worry?. *Netherlands Heart Journal*, **2013**, 21, 155-156	2.2	78
154	Palpitations in a 19-year-old man, take a second look. *Netherlands Heart Journal*, **2013**, 21, 208-209	2.2	1
153	HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*, **2013**, 10, 1932-63	6.7	1211
152	Palpitations, once again. *Netherlands Heart Journal*, **2013**, 21, 47-47	2.2	78
151	Palpitations, once again. *Netherlands Heart Journal*, **2013**, 21, 50-50	2.2	78
150	Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2013**, 10, 542-7	6.7	66
149	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. *Europace*, **2013**, 15, 1389-406	3.9	379
148	Myocardial energetic impairment differs in pre-hypertrophic carriers with mutations in MYH7 and MYBPC3 - a PET and MRI study. *European Heart Journal*, **2013**, 34, P3885-P3885	9.5	
147	Exome sequencing of multiple affected individuals from an Irish family with Brugada Syndrome uncovers a novel locus for the disorder. *European Heart Journal*, **2013**, 34, P2289-P2289	9.5	
146	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. *Europace*, **2013**, 15, 1042-9	3.9	47
145	Andersen-Tawil syndrome, scarier for the doctor than for the patient? Who, when, and how to treat. *Europace*, **2013**, 15, 1690-2	3.9	11
144	Characterisation of familial idiopathic ventricular fibrillation linked to DPP6. *European Heart Journal* , **2013**, 34, 4559-4559	9.5	0
143	Unique cardiac Purkinje fiber transient outward current β-subunit composition: a potential molecular link to idiopathic ventricular fibrillation. *Circulation Research*, **2013**, 112, 1310-22	15.7	61
142	Yield of molecular and clinical testing for arrhythmia syndromes: report of 15 years' experience. *Circulation*, **2013**, 128, 1513-21	16.7	106
141	The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 91-100	6.4	64
140	Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. *Circulation Research*, **2013**, 112, 689-97	15.7	41
139	Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside. *Heart*, **2013**, 99, 497-504	5.1	45
138	Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. *European Journal of Heart Failure*, **2013**, 15, 376-84	12.3	97

137	Congenital Long QT Syndrome: An Update and Present Perspective in Saudi Arabia. *Frontiers in Pediatrics*, **2013**, 1, 39	3.4	10
136	Brugada phenocopy: new terminology and proposed classification. *Annals of Noninvasive Electrocardiology*, **2012**, 17, 299-314	1.5	160
135	Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. *Heart Rhythm*, **2012**, 9, 892-8	6.7	43
134	The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *Journal of the American College of Cardiology*, **2012**, 60, 1933-9	15.1	174
133	Brugada syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 606-16	6.4	186
132	Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. *American Heart Journal*, **2012**, 163, 753-760.e2	4.9	130
131	Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. *Journal of the American College of Cardiology*, **2012**, 59, 493-500	15.1	353
130	Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. *Journal of the American College of Cardiology*, **2012**, 60, 144-56	15.1	109
129	Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. *Journal of the American College of Cardiology*, **2012**, 60, 2092-9	15.1	168
128	Narrow QRS complexes intervening wide QRS complexes. *Netherlands Heart Journal*, **2012**, 20, 518-518	2.2	78
127	Narrow QRS complexes intervening wide QRS complexes. *Netherlands Heart Journal*, **2012**, 20, 520-520	2.2	78
126	The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. *European Journal of Human Genetics*, **2012**, 20, 1071-7	5.3	23
125	SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility. *PLoS ONE*, **2012**, 7, e42037	3.7	55
124	Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. *Europace*, **2012**, 14, 175-83	3.9	131
123	TGF□nducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. *Journal of Cellular Biochemistry*, **2012**, 113, 1896-903	4.7	18
122	Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. *Circulation*, **2012**, 125, 3079-91	16.7	200
121	Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome. *Circulation: Cardiovascular Genetics*, **2012**, 5, 519-28		48
120	Mortality of inherited arrhythmia syndromes: insight into their natural history. *Circulation: Cardiovascular Genetics*, **2012**, 5, 183-9		31

119	Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 748-56	6.4	108
118	A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. *Circulation: Cardiovascular Genetics*, **2012**, 5, 91-9		127
117	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. *European Journal of Heart Failure*, **2012**, 14, 1199-207	12.3	270
116	Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. *Circulation*, **2012**, 125, 1988-96	16.7	138
115	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. *Heart Rhythm*, **2011**, 8, 1546-52	6.7	17
114	Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. *Journal of the American College of Cardiology*, **2011**, 57, 51-9	15.1	205
113	Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. *Journal of the American College of Cardiology*, **2011**, 57, 2244-54	15.1	271
112	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*, **2011**, 8, 1308-39	6.7	737
111	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Europace*, **2011**, 13, 1077-109	3.9	557
110	Sodium channelopathies: do we really understand what's going on?. *Journal of Cardiovascular Electrophysiology*, **2011**, 22, 590-3	2.7	4
109	Somatic mosaicism contributes to phenotypic variation in Timothy syndrome. *American Journal of Medical Genetics, Part A*, **2011**, 155A, 2578-83	2.5	53
108	Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. *European Heart Journal*, **2011**, 32, 1161-70	9.5	60
107	Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. *Heart Rhythm*, **2011**, 8, 1537-43	6.7	93
106	Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. *Circulation Research*, **2011**, 108, 884-97	15.7	148
105	A complex double deletion in LMNA underlies progressive cardiac conduction disease, atrial arrhythmias, and sudden death. *Circulation: Cardiovascular Genetics*, **2011**, 4, 280-7		23
104	Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports. *Europace*, **2011**, 13, 11-3	3.9	1
103	Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. *Circulation*, **2011**, 124, 2187-94	16.7	136
102	ECG quantification of myocardial scar does not differ between primary and secondary prevention ICD recipients with ischemic heart disease. *PACE - Pacing and Clinical Electrophysiology*, **2010**, 33, 192-7	1.6	2

101	Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. *Nature Genetics*, **2010**, 42, 688-691	36.3	132
100	The Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 283-90	6.4	102
99	An entirely subcutaneous implantable cardioverter-defibrillator. *New England Journal of Medicine*, **2010**, 363, 36-44	59.2	518
98	Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. *Circulation*, **2010**, 121, 635-43	16.7	563
97	The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. *European Heart Journal*, **2010**, 31, 842-8	9.5	54
96	An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. *Heart Rhythm*, **2010**, 7, 33-46	6.7	515
95	Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. *Journal of the American College of Cardiology*, **2010**, 55, 789-97	15.1	113
94	The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. *Journal of the American College of Cardiology*, **2010**, 55, 1955-61	15.1	149
93	Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment?. *Journal of the American College of Cardiology*, **2010**, 55, 2570-6	15.1	75
92	Laminopathy presenting as familial atrial fibrillation. *International Journal of Cardiology*, **2010**, 145, 394-396	3.2	15
91	The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 95-105	5.8	34
90	The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 543-53	5.8	251
89	Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. *Heart Rhythm*, **2010**, 7, 1383-9	6.7	126
88	Sudden death in the young: what do we know about it and how to prevent?. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 96-104	6.4	62
87	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. *Netherlands Heart Journal*, **2010**, 1	2.2	
86	Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. *Netherlands Heart Journal*, **2010**, 18, 248-54	2.2	55
85	Recurrent and founder mutations in the Netherlands : Plakophilin-2 p.Arg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Netherlands Heart Journal*, **2010**, 18, 583-91	2.2	29
84	SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. *Circulation: Cardiovascular Genetics*, **2009**, 2, 552-7		211

83	Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. *Circulation*, **2009**, 120, 1752-60	16.7	265
82	Genetically determined differences in sodium current characteristics modulate conduction disease severity in mice with cardiac sodium channelopathy. *Circulation Research*, **2009**, 104, 1283-92	15.7	63
81	Exercise-induced ECG changes in Brugada syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 531-9	6.4	81
80	Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. *American Journal of Medical Genetics, Part A*, **2009**, 149A, 602-12	2.5	92
79	Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective. *American Journal of Medical Genetics, Part A*, **2009**, 149A, 1444-51	2.5	50
78	Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nature Medicine*, **2009**, 15, 380-3	50.5	436
77	Primary prevention with ICDs, are we on the right track?. *Netherlands Heart Journal*, **2009**, 17, 92-4	2.2	6
76	Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. *Netherlands Heart Journal*, **2009**, 17, 422-8	2.2	52
75	Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. *American Journal of Human Genetics*, **2009**, 84, 468-76	11	121
74	The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. *Journal of the American College of Cardiology*, **2009**, 54, 2065-74	15.1	234
73	Genotype-phenotype aspects of type 2 long QT syndrome. *Journal of the American College of Cardiology*, **2009**, 54, 2052-62	15.1	187
72	Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). *Heart Rhythm*, **2009**, 6, 1335-41	6.7	272
71	Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. *Heart Rhythm*, **2009**, 6, 1297-303	6.7	305
70	IK1 modulates the U-wave: insights in a 100-year-old enigma. *Heart Rhythm*, **2009**, 6, 393-400	6.7	25
69	Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. *Heart Rhythm*, **2009**, 6, 341-8	6.7	182
68	Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 537-49	4	12
67	Slow and discontinuous conduction conspire in Brugada syndrome: a right ventricular mapping and stimulation study. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 379-86	6.4	101
66	Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. *New England Journal of Medicine*, **2008**, 358, 2024-9	59.2	306

65	A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. *Circulation Research*, **2008**, 102, 1433-42	15.7	127
64	Fever increases the risk for cardiac arrest in the Brugada syndrome. *Annals of Internal Medicine*, **2008**, 149, 216-8	8	105
63	Channelopathies in children and adults. *PACE - Pacing and Clinical Electrophysiology*, **2008**, 31 Suppl 1, S41-5	1.6	10
62	Activation delay and VT parameters in arrhythmogenic right ventricular dysplasia/cardiomyopathy: toward improvement of diagnostic ECG criteria. *Journal of Cardiovascular Electrophysiology*, **2008**, 19, 775-81	2.7	91
61	Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. *Journal of Clinical Investigation*, **2008**, 118, 2552-61	15.9	64
60	A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 1060-6	2.7	65
59	Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system?. *European Heart Journal*, **2007**, 28, 575-80	9.5	74
58	Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation. *Cardiovascular Research*, **2007**, 76, 418-29	9.9	33
57	Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. *European Heart Journal*, **2007**, 28, 2126-33	9.5	118
56	Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. *Circulation*, **2007**, 116, 1569-76	16.7	184
55	Clinical aspects and prognosis of Brugada syndrome in children. *Circulation*, **2007**, 115, 2042-8	16.7	232
54	Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. *Circulation*, **2007**, 115, 2481-9	16.7	326
53	The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. *Circulation*, **2007**, 116, 2366-75	16.7	130
52	Inherited arrhythmia syndromes. *Circulation Journal*, **2007**, 71 Suppl A, A12-9	2.9	6
51	Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. *Circulation*, **2006**, 113, 338-44	16.7	186
50	Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications. *Circulation*, **2006**, 114, 2096-103	16.7	107
49	Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation*, **2006**, 113, 1650-8	16.7	276
48	Spontaneous electrocardiographic fluctuations in Brugada syndrome: does it matter?. *European Heart Journal*, **2006**, 27, 2493-4	9.5	12

47	Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias. *Europace*, **2005**, 7, 77-84	3.9	27
46	Brugada syndrome: report of the second consensus conference. *Heart Rhythm*, **2005**, 2, 429-40	6.7	329
45	Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: a survey. *Clinical Genetics*, **2005**, 68, 360-8	4	19
44	Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties. *Acta Physiologica Scandinavica*, **2005**, 185, 291-301		42
43	Exercise related syncope: when it is not the heart. *Clinical Autonomic Research*, **2005**, 15, 64-64	4.3	
42	Substitution of a conserved alanine in the domain IIIS4-S5 linker of the cardiac sodium channel causes long QT syndrome. *Cardiovascular Research*, **2005**, 67, 459-66	9.9	13
41	Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?. *Cardiovascular Research*, **2005**, 67, 367-78	9.9	275
40	Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. *Circulation*, **2005**, 112, 207-13	16.7	320
39	Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation*, **2005**, 111, 659-70	16.7	1356
38	Genetics of cardiac arrhythmias. *Heart*, **2005**, 91, 1352-8	5.1	102
37	Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. *Journal of Medical Genetics*, **2005**, 42, 863-70	5.8	201
36	Letter regarding article by McNair et al, "SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia". *Circulation*, **2005**, 112, e9; author reply e9-10	16.7	5
35	Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. *Circulation*, **2004**, 109, 2394-7	16.7	514
34	Delay in right ventricular activation contributes to Brugada syndrome. *Circulation*, **2004**, 109, 1272-7	16.7	154
33	Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. *Circulation Research*, **2003**, 92, 976-83	15.7	118
32	Relation between basic and clinical electrophysiologic characteristics in Brugada syndrome: facts or fiction?. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 412-4	2.7	4
31	Diagnostic performance of various QTc interval formulas in a large family with long QT syndrome type 3: Bazett's formula not so bad after all. *Annals of Noninvasive Electrocardiology*, **2003**, 8, 269-74	1.5	10
30	The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. *European Heart Journal*, **2003**, 24, 1848-53	9.5	107

29	The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. *Journal of Medical Genetics*, **2003**, 40, 141-5	5.8	62
28	Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. *Circulation Research*, **2003**, 92, 159-68	15.7	190
27	?20??????????? ??????????. *Japanese Journal of Electrocardiology*, **2003**, 23, 415-416	0	
26	Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2002**, 91, e21-6	15.7	304
25	Gender differences in the long QT syndrome: effects of beta-adrenoceptor blockade. *Cardiovascular Research*, **2002**, 53, 770-6	9.9	31
24	Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation*, **2002**, 106, 2514-9	16.7	631
23	Is There a Role for Implantable Cardioverter Defibrillators in Long QT Syndrome?. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, S110-S113	2.7	10
22	Proposed diagnostic criteria for the Brugada syndrome. *European Heart Journal*, **2002**, 23, 1648-54	9.5	191
21	Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 630-6	2.7	117
20	Adenosine induced ventricular arrhythmias in the emergency room. *PACE - Pacing and Clinical Electrophysiology*, **2001**, 24, 450-5	1.6	37
19	Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. *PACE - Pacing and Clinical Electrophysiology*, **2001**, 24, 1420-2	1.6	127
18	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*, **2001**, 103, 89-95	16.7	1363
17	Proarrhythmia Related to Sodium Channel Blockade II: Postulated Mechanisms of Brugada Syndrome and Their Possible Involvement in Class IC Drug-Induced Ventricular Arrhythmias During Ischemia. *Journal of Interventional Cardiac Electrophysiology*, **2000**, 4, 217-221		1
16	Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. *Circulation Research*, **2000**, 86, E91-7	15.7	236
15	Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. *Cardiovascular Research*, **1999**, 44, 507-17	9.9	134
14	"Brugada" syndrome: clinical data and suggested pathophysiological mechanism. *Circulation*, **1999**, 99, 666-73	16.7	364
13	A single Na(+) channel mutation causing both long-QT and Brugada syndromes. *Circulation Research* , **1999**, 85, 1206-13	15.7	526
12	Cardiac conduction defects associate with mutations in SCN5A. *Nature Genetics*, **1999**, 23, 20-1	36.3	461

11	Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity?. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 219-23	2.7	28
10	Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2). *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 229-33	2.7	35
9	Novel KCNQ1 and HERG missense mutations in Dutch long-QT families. *Human Mutation*, **1999**, 13, 301-10	4.7	47
8	Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). *Journal of the American College of Cardiology*, **1999**, 33, 327-32	15.1	246
7	A new, sympathetic look at KATP channels in the heart. *Cardiovascular Research*, **1999**, 43, 17-9	9.9	1
6	Proarrhythmia Related to Sodium Channel Blockade: Mechanisms, Monitoring, Prevention and Management. *Journal of Interventional Cardiac Electrophysiology*, **1998**, 2, 136-141		6
5	Ion channels, the QT interval, and arrhythmias. *PACE - Pacing and Clinical Electrophysiology*, **1997**, 20, 2048-51	1.6	12
4	Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. *Journal of Neurology*, **1997**, 244, 657-63	5.5	55
3	Subpopulations of Cardiomyocytes in the Embryonic Chicken Heart. *Annals of the New York Academy of Sciences*, **1990**, 588, 354-356	6.5	1
2	Glibenclamide inhibition of ATP-sensitive K+ channels and ischemia-induced K+ accumulation in the mammalian heart. *Pflugers Archiv European Journal of Physiology*, **1989**, 414 Suppl 1, S176	4.6	7
1	Ventricular Arrhythmias and Sudden Death80-95		